ReviewTransplantation and cellular therapy2025
The Caregiver Paradigm in Hematopoietic Cell Transplant: Current and Future Directions.
Review in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study.Transplantation and cellular therapy · 2026Trial
- Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.Transplantation and cellular therapy · 2025Review
- Proceedings From the Second Reimagining Caregiver Workshop: Addressing Caregiver Requirements for Hematopoietic Cell Transplant.Transplantation and cellular therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Many transplant centers (TCs) require a patient to have a caregiver 24 hours a day, 7 days a week for a minimum timeframe to proceed with an allogeneic hematopoietic cell transplant (alloHCT). However, this requirement varies across TCs, with timing of requirements varying from no requirements up to 180 days, and there is inconclusive evidence to support the need for this requirement. The current caregiver requirement paradigm can limit access for many patients, besides causing a significant physical, emotional, and financial burden on caregivers. This article reviews literature on the current alloHCT caregiver paradigm and identifies barriers to change. Lastly, it highlights alternative caregiving models that are currently being implemented, as well as opportunities for future directions to improve access, including the need for research on interventions such as remote monitoring, community partnerships, policy changes, and enhanced screening. There is a need for evidence-based patient-centered care models to transform the caregiver paradigm to ensure that all patients can receive the treatment they need, irrespective of whether they have a caregiver. The future of post-alloHCT care demands a shift towards patient-centered, flexible caregiving models that accommodate the diverse needs and circumstances of patients. Such evidence-based changes in the paradigm can help improve access to, and outcomes for, alloHCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.